期刊文献+

聚乙二醇化盐酸多柔比星脂质体注射液药代动力学的对比研究 被引量:1

A Comparison of Pharmacokinetics of PEGylated Liposomal Doxorubicin Hydrochloride Injections
原文传递
导出
摘要 为了评价盐酸多柔比星脂质体受试制剂(S)和进口同规格参比制剂(R)的一致性,对比研究了2种制剂单次静脉注射后,在SD大鼠和荷人卵巢癌A-2780肿瘤裸鼠的血清和不同组织内的药物浓度。建立了HPLC-FLD法,用于测定SD大鼠血清、荷瘤裸鼠血清和肿瘤中多柔比星(1)总含量(即游离1和PEG化脂质体中1的含量总和)和PEG化脂质体中1含量,以及大鼠不同组织中1的总含量。结果显示,两种制剂以5 mg/kg的剂量,尾静脉注射给予SD大鼠,给药后1 h、24 h和72 h,分别对9个组织脏器中的1总含量进行双单侧检验分析,在P=0.05水平上2种制剂的差异不显著;2种制剂以10 mg/kg的剂量,尾静脉注射给予荷瘤裸鼠,给药后1 h、24 h和72 h分别对瘤内1总含量和PEG化脂质体中1含量进行双单侧检验分析,在P=0.05水平上2种制剂的差异也不显著。由此推断,受试制剂与参比制剂在动物体内的分布无统计学差异。 This paper aimed to study the distribution of PEGylated liposomal doxorubicin (PLD) hydrochloride injection in different tissues of SD rats and A-2780 tumor-bearing nude mice after single dose intravenous administration with the marketed similar foreign preparation as control, and provide supports for follow-up studies. An analytical method had been established for determining the concentrations of doxorubicin (1), 1 in PLD and their total value in rat serum, nude mouse serum and tumors as well as 1 in rat tissues. After intravenous administration of test preparation or reference preparation to SD rats at dose of 5 mg/kg, the total concentrations of 1 in nine tissues (heart, liver, spleen, lung, kidney, brain, intestinal, marrow and skin), including free ones and liposomes, at time points of 1, 24 and 72 h were determined. Besides, the total concentrations of 1 and 1 in PLD in tumors of A-2780 tumor-bearing nude mice treated with PLD injection at different time points of 1, 24 and 72 h were also determined. The results showed that there were no statistic differences between test and reference PLD injections in 1 distribution in nine tissues of SD rats as well as in tumors of nude mice at the 0.05 level. It was concluded that there was no statistic difference in the distribution of test preparation and reference product in animals.
出处 《中国医药工业杂志》 CAS CSCD 北大核心 2017年第11期1617-1622,共6页 Chinese Journal of Pharmaceuticals
关键词 盐酸多柔比星脂质体注射液 药代动力学 组织分布 PEGylated liposomal doxorubicin hydrochloride injection pharmacokinetics tissue distribution
  • 相关文献

参考文献3

二级参考文献51

  • 1Sakae U,Kazuo M,Osamu I,et al. Enhanced tumor targeting and improved antitumor activity of doxorubicin by longcirculating liposomes containing amphipathic poly (ethylene glycol)[J].Int J P karm,1995,126(1):41-48.
  • 2Woodle MC,Martin FJ,Yau-Young A,et al.Liposomes with enhanced circulation time:US,5013556[P].1991-05-07.
  • 3Vaage J,Barberá-Guillem E,Abra R,et al.Tissue distribution and therapeutic effect of intravenous free or encapsulated liposomal doxorubicin on human prostate carcinoma xenografts[J].Cancer,1994,73 (5):1478-1484.
  • 4Saltiel E,McGuire W.Doxorubicin (adriamycin) cardiomyopathy-A critical review[J].West J Med,1983,139(3):332-341.
  • 5Working PK,Dayan AD.Pharmacological-toxicological expert report.CAELYX (Stealth liposomal doxorubicin HCI)[J].Hum Exp Toxicol,1996,15(9):751-785.
  • 6Ferrandina G,Ludovisi M,Lorusso D,et al.Phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in progressive or recurrent ovarian cancer[J].J Clin Oncol,2008.26(6):890-6.
  • 7Sehouli J,Camara O,Schmidt M,et al.Pegylated liposomal doxorubicin (CAELYX) in patients with advanced ovarian cancer:results of a German multicenter observational study[J].Cancer Chemother Pharmacol,2009,64(3):585-91.
  • 8Pignata S,Scambia G,Savarese A,et al.Carboplatin and pegylated liposomal doxorubicin for advanced ovarian cancer:preliminary activity results of the MITO-2 phase III trial[J].Oncology,2009.76(1):49-54.
  • 9Markman M,Moon J,Wilczynski S,et al.Single agent carboplatin versus carboplatin plus pegylated liposomal doxorubicin in recurrent ovarian cancer:final survival results of a SWOG (S0200) phase 3 randomized trial[J].Gynecol Oncol,2010.116(3):323-5.
  • 10Kavanagh JJ,Levenback CF,Ramirez PT,et al.Phase 2 study of canfosfamide in combination with pegylated liposomal doxorubicin in platinum and paclitaxel refractory or resistant epithelial ovarian cancer[J].J Hematol Oncol,2010.3(1):9.

共引文献36

同被引文献2

引证文献1

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部